Senior Vice President and Chief Medical Officer at Theratechnologies.
FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy
March 25th 2025Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.
Read More